Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
Grace Therapeutics reported a fiscal 2026 net loss of $7.8 million, or $0.47 per share, an improvement from the $9.6 million loss reported in the prior year. The company ended the period with $17.0 million in cash, stating it has sufficient runway to fund operations for at least the next 12 months. Regarding the GTx-104 NDA, the company confirmed that the April FDA Complete Response Letter cited only CMC and non-clinical issues, with no clinical deficiencies identified. A Type A meeting has been scheduled to clarify the path forward for the NDA resubmission.
Key figures
- Cash
- $17.0 million
- Net Loss
- $7.8 million
- Cash Runway
- at least 12 months
- Ga expenses
- $8.7 million
- Rd expenses
- $2.4 million
- Net cash decrease
- $5.1 million
- Shares outstanding
- 16024026
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.